adjuvant + TIV

adjuvant + TIV is a combination vaccine intervention consisting of a Trivalent Inactivated Influenza Virus (TIV) vaccine and an undisclosed adjuvant. This formulation was utilized as a comparator or component in clinical trials sponsored by Immune Targeting Systems Ltd, specifically a Phase 1 study (NCT01537120) involving healthy elderly volunteers aged 65 to 74. The TIV component is a standard vaccine containing inactivated hemagglutinin from three influenza strains (typically two A subtypes and one B lineage), while the adjuvant is intended to enhance the immunogenicity of the vaccine in older adults, who often exhibit reduced responses to conventional influenza vaccines.

Other names

adjuvant + TIV-Immune Targeting Systems Ltd-Influenza AAdjuvant + TIV